SCHEMBL1128401

SCHEMBL1128401

Cc1cc(O)ccc1NS(C)(=O)=O

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYTH2 Q99418 4/20 0.63
EP300 Q09472 1/20 0.47
KAT2B Q92831 1/20 0.47
KAT8 Q9H7Z6 1/20 0.47
KEAP1 Q14145 1/20 0.47
NFE2L2 Q16236 1/20 0.47
TNIK Q9UKE5 2/20 0.45
GAA P10253 5/20 0.44
ALDH1A1 P00352 3/20 0.44
LMNA P02545 3/20 0.44
KDM4E B2RXH2 2/20 0.44
MAPT P10636 2/20 0.44
ALOX15 P16050 1/20 0.44
CASP1 P29466 1/20 0.44
CASP7 P55210 1/20 0.44
RUNX1 Q01196 1/20 0.44
CBFB Q13951 1/20 0.44
HSD17B10 Q99714 1/20 0.44
KMT2A Q03164 2/20 0.43
PKM P14618 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28543766 0.85 CYTH2 (0.63) CYTH2TNIKGAAALDH1A1LMNA
SCHEMBL2760280 0.80 FKBP1A (0.56) CYTH2KEAP1NFE2L2ALDH1A1MAPT
SCHEMBL2767867 0.79 EP300 (0.46) EP300KAT2BKAT8TNIK
SCHEMBL7723614 0.78 ADRA2A (0.58) EP300KAT2BKAT8LMNAHSD17B10
SCHEMBL11561858 0.78 FKBP1A (0.54) CYTH2KEAP1NFE2L2ALDH1A1MAPT
SCHEMBL7178299 0.78 CYTH2 (0.73) CYTH2EP300KAT2BKAT8KEAP1
SCHEMBL2760278 0.77 L3MBTL1 (0.53) CYTH2EP300KAT2BKAT8KEAP1
SCHEMBL15108250 0.77 PLA2G7 (0.49) KEAP1NFE2L2TNIKKMT2APKM
SCHEMBL1542958 0.77 ALDH1A1 (0.53) KEAP1NFE2L2TNIKALDH1A1MAPT
SCHEMBL2760253 0.77 MAPT (0.48) KEAP1NFE2L2GAAALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8188098-B2 GPR119 receptor agonists HOFFMANN-LA ROCHE INC. (US) 2012-05-29 US disclosed
EP-2283019-A1 GPR119 RECEPTOR AGONISTS F. Hoffmann-La Roche AG (CH) 2011-02-16 EP disclosed
WO-2009141238-A1 GPR119 RECEPTOR AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2009-11-26 WO disclosed
US-20090286812-A1 GPR119 Receptor Agonists ERICKSON SHAWN DAVID 2009-11-19 US disclosed
US-4259469-A DESIRABLE SOLUBILITY CHARACTERISTICS FOR USE IN PHOTOLITHOGRAPHY EASTMAN KODAK COMPANY (US) 1981-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286812-A1 GPR119 Receptor Agonists GPR119, GPR27, GPR139 CYTH2 1888/4885EP300 1304/4885KAT2B 2948/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.